Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from 8 weeks versus 12 weeks of sofosbuvir–velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2024 · External reference
Unresolved reference
2016 · External reference
National prescribing trends of direct-acting antivirals for hepatitis C
10.1001/jama.2026.3328 · 2026 · External reference
Number of people treated for hepatitis C virus infection in 2014–2023 and applicable lessons for new HBV and HDV therapies
10.1016/j.jhep.2025.01.013 · 2025 · External reference
Hepatitis C cascade of care in the direct-acting antivirals era: a meta-analysis
10.1016/j.amepre.2023.06.016 · 2023 · External reference
Global hepatitis C elimination: updates, challenges, and opportunities from real-world experiences in Europe and North America
10.1097/hep.0000000000001548 · 2025 · External reference
Progress toward the elimination of hepatitis B and hepatitis C in the country of Georgia, April 2015-April 2024
10.15585/mmwr.mm7330a1 · 2024 · External reference
Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting
10.1016/j.jhep.2019.07.006 · 2019 · External reference
Adherence to once-daily and twice-daily direct-acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy
10.1093/cid/ciz1089 · 2020 · External reference
Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis
10.1111/jvh.13239 · 2020 · External reference
Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study
2022 · External reference
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
10.1053/j.gastro.2004.11.018 · 2005 · External reference
Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial)
10.1371/journal.pone.0285725 · 2023 · External reference
Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection
10.1056/nejmoa1702417 · 2018 · External reference
Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat
10.1002/sim.2244 · 2006 · External reference
Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection
10.1056/nejmoa1512610 · 2015 · External reference
Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection
10.1056/nejmoa1512612 · 2015 · External reference
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts
10.1111/liv.14537 · 2020 · External reference
A cost-effectiveness analysis of shortened direct-acting antiviral treatment in genotype 1 noncirrhotic treatment-naive patients with chronic hepatitis C virus
10.1016/j.jval.2018.12.011 · 2019 · External reference
Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial
10.7326/m15-1000 · 2015 · External reference
Efficacy and safety of sofosbuvir-based regimens in hepatitis C patients with decompensated cirrhosis: a systematic review and meta-analysis
2023 · External reference
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: a real-world nationwide hepatitis C virus registry programme in Taiwan
10.1111/liv.14849 · 2021 · External reference
Review article: HCV genotype 3—the new treatment challenge
10.1111/apt.12646 · 2014 · External reference
Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals
10.1016/j.jhep.2017.01.020 · 2017 · External reference
Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study
10.1016/j.jhep.2023.12.020 · 2024 · External reference
Real-life data of hepatitis C treatment with direct acting antiviral therapy in persons injecting drugs or on opioid substitution therapy
10.1007/s15010-024-02433-4 · 2025 · External reference
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial
10.1016/s2468-1253(21)00397-6 · 2022 · External reference
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
10.1056/nejmoa1402355 · 2014 · External reference
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection
10.1002/hep.29005 · 2017 · External reference
No difference in effectiveness of 8 vs 12 weeks of ledipasvir and sofosbuvir for treatment of hepatitis C in black patients
10.1016/j.cgh.2018.03.003 · 2018 · External reference
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
10.1136/gutjnl-2017-315906 · 2019 · External reference
EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis
10.1016/j.jhep.2015.04.006 · 2015 · External reference
